{"filings":[{"id":1224796,"accession_number":"0001193125-26-279803","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2026-06-23T21:28:13+00:00","items":["8.01"],"status":"ready","headline":"Enanta loses Federal Circuit appeal; Paxlovid patent claims invalidated","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Federal Circuit affirmed Dec 2024 summary judgment, ruling claims of U.S. Patent No. 11,358,953 invalid.","Patent covered Pfizer's COVID-19 antiviral Paxlovid (nirmatrelvir; ritonavir).","Enanta had sought damages for infringement; appeal loss eliminates potential royalty stream.","Decision issued on June 23, 2026 by the U.S. Court of Appeals for the Federal Circuit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-06-23","daily_digest_url":"/daily/2026-06-23","daily_digest_rank":6},{"id":1120396,"accession_number":"0001193125-26-274950","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2026-06-18T11:12:58+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enanta advances zelicapavir to registrational Phase 2b/3 trial in high-risk adults with RSV; pediatric Phase 2b planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Registrational Phase 2b/3 trial in high-risk adults (≥75 yrs, COPD, CHF) to start 4Q 2026; Phase 2b topline data expected 2027.","Phase 2b pediatric trial (28 days-36 months) to start 3Q 2026; topline data expected 2027; conducted with Penta Foundation and Chiang Mai University.","FDA End-of-Phase 2 meeting successful; trial design includes 800mg oral zelicapavir once daily for 7 days vs placebo.","Enanta estimates global market opportunity for oral RSV antiviral >$2B; US addressable population >3M patients.","No available treatment options for RSV; zelicapavir could be first antiviral therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":12890,"accession_number":"0001193125-26-216735","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2026-05-11T20:05:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta Q2 FY2026 net loss narrows to $13.1M; Phase 1 trial started for EDP-978","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $17.2M from AbbVie royalties (up from $14.9M YoY); net loss $13.1M ($0.45/share) vs $22.6M loss YoY.","Cash $227M; runway into fiscal 2029; R&D spend $19.4M (down from $28.1M due to lower RSV trial costs).","Phase 1 dosing initiated for oral KIT inhibitor EDP-978; topline data expected Q4 2026.","Zelicapavir pivotal study enabling with FDA; update planned in Q2 2026; exploring BD opportunities.","Litigation: Federal Circuit oral arguments vs Pfizer; decision by Sept 2026; UPC hearing Sept 29."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101943,"accession_number":"0001193125-26-125113","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Federal Circuit schedules May 11, 2026 oral argument for Enanta's patent appeal against Pfizer over Paxlovid","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Federal Circuit oral argument in Enanta's patent appeal against Pfizer (Paxlovid) set for May 11, 2026.","Enanta originally filed suit for infringement of U.S. Patent No. 11,358,953 related to Paxlovid.","Notice of appeal was filed on February 3, 2025.","The appeal is before the U.S. Court of Appeals for the Federal Circuit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101942,"accession_number":"0001193125-26-104109","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Enanta stockholders approve 1.6M share increase to 2019 Equity Plan; re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders re-elected Bruce L.A. Carter and Jay R. Luly as Class I directors with 20.3M and 24.7M votes for, respectively.","Amendment to 2019 Equity Incentive Plan approved (19.5M for, 5.4M against), increasing share reserve by 1,600,000 shares.","Advisory say-on-pay vote approved with 24.2M for, 692k against.","Ratification of PricewaterhouseCoopers as independent auditor for fiscal 2026 approved (26.8M for, 27k against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101941,"accession_number":"0001193125-26-042812","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta Q1 FY2026 net loss $11.9M ($0.42/sh); pipeline advances with zelicapavir and new immunology programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $18.6M from AbbVie royalties, up 9% vs $17.0M YoY; net loss narrowed to $11.9M from $22.3M.","Cash & securities $241.9M; runway expected into fiscal 2029.","Zelicapavir Phase 2b RSVHR showed 6.7-day improvement in symptom resolution for high-risk adults; Phase 3 enabling activities ongoing.","New MRGPRX2 immunology program introduced; development candidate selection expected in 2H 2026.","EDP-978 (oral KIT) IND on track for Q1 2026; EPS-3903 (oral STAT6) IND targeting 2H 2026."],"consensus_eps_estimate":-0.4978,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":18615000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118276,"accession_number":"0001193125-25-284633","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta Q4 net loss $0.87/sh, revenue $15.1M; cash $188.9M; RSV data positive, STAT6 candidate selected","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.7M ($0.87 loss per share) vs $28.8M loss ($1.36/sh) in Q4 2024.","Total revenue $15.1M from MAVYRET royalties; FY 2025 revenue $65.3M vs $67.6M prior year.","Ending cash $188.9M; plus $74.8M gross from Oct 2025 offering; runway into FY2029.","Zelicapavir Phase 2b in high-risk RSV adults met secondary endpoints; 2.2-day symptom resolution improvement.","Nominated EPS-3903 (STAT6 inhibitor) with >90% pSTAT6 suppression; IND target H2 2026; EDP-978 IND Q1 2026."],"consensus_eps_estimate":-0.8237,"consensus_eps_actual":-3.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":65324000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118275,"accession_number":"0001193125-25-226828","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2025-10-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Enanta Pharmaceuticals prices public offering of 6.5M shares at $10/share, expects ~$60.6M net proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["6,500,000 shares offered at $10.00 per share; underwriters have 30-day option for 975,000 more shares.","Expected net proceeds of approximately $60.6 million after underwriting discounts and offering expenses.","Offering expected to close on October 2, 2025, subject to customary closing conditions.","Underwriting agreement with J.P. Morgan, Jefferies, and Evercore dated September 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134726,"accession_number":"0001193125-25-221791","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enanta reports positive Phase 2b topline data for zelicapavir in high-risk RSV adults","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Phase 2b study of zelicapavir (formerly EDP-938) met primary endpoint in high-risk adults with RSV.","Topline results announced September 29, 2025; detailed data presented in slide presentation.","Zelicapavir is an oral antiviral; no specific efficacy or safety numbers disclosed in the 8-K.","Positive outcome supports advancement; further details expected in future medical meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134725,"accession_number":"0001193125-25-221527","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Zelicapavir shows 6.7-day symptom resolution improvement in high-risk RSV adults","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["6.7-day faster complete resolution of all 13 RSV symptoms in HR3 population (COPD/CHF/age≥75); 7.2-day improvement in total RiiQ.","Hospitalization rate 1.7% for zelicapavir vs 5.0% placebo; 2-day faster PGI-S improvement (p<0.05).","Robust antiviral effect: 4–5 day faster undetectable viral load; 23.5% vs 10.0% undetectable at end of treatment (p=0.0198).","Favorable safety: no treatment discontinuations; most common AEs diarrhea (3.3%) and asthma (2.5%).","Primary endpoint (time to mild LRTD symptoms) not met; data inform Phase 3 design and registrational endpoints."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134724,"accession_number":"0001193125-25-189691","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Enanta designates interim CFO and principal accounting officer during CFO medical leave","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Harry Trout (VP Finance) named interim principal financial officer; Katie Capps (Executive Director, Accounting) interim principal accounting officer.","Appointments effective Aug 26, 2025, while CFO Paul Mellett is on a medical leave of absence.","Trout joined Enanta in 2002; Capps joined in 2016; both have held increasing finance roles.","Neither interim officer has entered into new material plans or arrangements in connection with this appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134723,"accession_number":"0001193125-25-183719","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Enanta sues Pfizer in EU UPC for Paxlovid patent infringement","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed suit in Unified Patent Court (action 35071/2025) alleging Pfizer's Paxlovid infringes European Patent EP 4 051 265.","Action covers 18 EU countries participating in UPC; patent based on July 2020 application for coronavirus protease inhibitors.","European counterpart of US Patent 11,358,953, which is already subject to ongoing US litigation between Enanta and Pfizer.","Hearing expected within 12-month UPC target; decision within weeks thereafter, subject to appeal.","No damages determination yet; if infringement found, separate proceedings would assess damages."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134722,"accession_number":"0001193125-25-177941","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta Q3 net loss $18.3M ($0.85/sh); RSV topline data due Sept","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $18.3M from AbbVie royalties; net loss narrowed vs $22.7M Q3 2024.","Cash & securities $204.1M; cash runway into fiscal 2028.","RSVHR Phase 2b fully enrolled (186 patients); topline data expected September.","IND-enabling studies ongoing for oral KIT inhibitor EPS-1421; STAT6 candidate selection in 2H 2025.","AbbVie received FDA approval for expanded MAVYRET indication in acute HCV."],"consensus_eps_estimate":-1.0414,"consensus_eps_actual":-2.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":50199000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151630,"accession_number":"0000950170-25-069155","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta Q2 net loss narrows to $22.6M; RSV study enrollment target met","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $14.9M, down 13% YoY from $17.1M; net loss $22.6M ($1.06 loss per share) vs $31.2M ($1.47) in prior year.","Cash and marketables $193.4M at March 31; plus $33.8M tax refund in April; expects runway into fiscal 2028.","Phase 2 RSVHR study of zelicapavir met enrollment target of 180 high-risk adults; topline data expected late Q3 2025.","STAT6 program: plan to select development candidate in 2H 2025; KIT inhibitor EPS-1421 IND-enabling studies ongoing.","Filed opening brief in patent infringement appeal against Pfizer over Paxlovid; original case filed June 2022."],"consensus_eps_estimate":-1.302,"consensus_eps_actual":-2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":31885000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170479,"accession_number":"0000950170-25-040230","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Enanta stockholders approve 800k-share increase to 2019 equity plan; re-elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to 2019 Equity Incentive Plan, adding 800,000 shares (11,435,985 for, 4,085,303 against).","Mark G. Foletta and Lesley Russell re-elected as Class III directors until 2028 annual meeting.","Advisory vote on executive compensation passed (14,516,861 for, 1,039,888 against); frequency set to annual.","PricewaterhouseCoopers LLP ratified as independent auditor for fiscal 2025 (17,740,127 for, 72,357 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170478,"accession_number":"0000950170-25-017035","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta Q1 net loss narrows to $22.3M; RSV Phase 2 topline data due Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $22.3M (-$1.05/sh) vs loss $33.4M (-$1.58/sh) YoY; revenue $17M from MAVYRET royalties.","Cash & securities $216.7M; expects runway into FY2028.","RSV zelicapavir Phase 2 RSVHR top-line data expected Q3 2025; Dec 2024 pediatric study showed antiviral effect.","Immunology: EPS-1421 KIT inhibitor IND studies ongoing; STAT6 candidate selection H2 2025; third program announced 2025.","Filed appeal in patent lawsuit against Pfizer over Paxlovid (Feb 3, 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":16959000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187468,"accession_number":"0001193125-24-272936","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Enanta reports positive Phase 2 data for zelicapavir in pediatric RSV: 1.4 log viral load drop at Day 5","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Part 2 primary endpoint: 1.4 log viral load decline at Day 5 vs placebo (n=34 zelicapavir, n=10 placebo).","Prespecified early-treatment subset (within 3 days of symptom onset): 1.2 log decline at Day 5 vs placebo.","96 patients (70 zelicapavir, 26 placebo) aged 28 days to 36 months; no AEs leading to discontinuation.","Dose selected: 5 mg/kg for ≥28 days to <12 months; 7.5 mg/kg for ≥12 to ≤36 months.","Symptom tool RESOLVE-P showed trend toward reduction but data available for only 15 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187467,"accession_number":"0000950170-24-130553","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta reports FY2024 revenue $67.6M, net loss $116M; RSV & immunology pipelines advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $14.6M (down 23% YoY); full-year $67.6M vs $79.2M due to lower MAVYRET royalties.","Net loss Q4 $28.8M ($1.36/shr); full-year $116.0M ($5.48/shr) vs $133.8M prior year.","Cash & securities $248.2M at Sept 30, 2024; runway expected into fiscal 2027.","RSVPEDs zelicapavir Phase 2 topline data due December 2024; EDP-323 Phase 2a met endpoints (p<0.0001).","Immunology expansion: KIT inhibitor EPS-1421 nominated; new STAT6 discovery program initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":67635000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203979,"accession_number":"0000950170-24-090722","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2024-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta reports Q3 net loss $22.7M, cash $272.6M; RSV trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $18.0M (royalty from AbbVie's MAVYRET); net loss $22.7M ($1.07 EPS) vs $39.1M loss a year ago.","Cash, equivalents and securities $272.6M at June 30, 2024; expects runway through Q3 FY2027.","Completed enrollment in RSVPEDs Phase 2 study of zelicapavir in pediatric RSV; topline data expected Q4 2024.","EDP-323 Phase 2a challenge study completed; topline data expected late Q3 2024.","Legal expenses increased due to patent infringement lawsuit against Pfizer; no Q3 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":53028000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220641,"accession_number":"0000950170-24-053532","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta Q2 net loss $31.2M; cash $300.3M; RSV data readouts expected in 2H 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Fiscal Q2 2024 revenue $17.1M (AbbVie HCV royalty); net loss $31.2M ($1.47 loss/share) vs $37.7M loss a year ago.","Cash, equivalents, and marketable securities total $300.3M; expected runway through Q3 FY2027.","Zelicapavir Phase 2 pediatric RSV data expected 2H 2024; EDP-323 challenge study data expected Q3 2024.","KIT inhibitor development candidate for CSU targeted Q4 2024; second immunology program planned in 2024.","Expense guidance updated: R&D $125M-$145M, G&A $50M-$60M due to immunology/RSV efforts and Pfizer patent lawsuit."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":35057000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240266,"accession_number":"0000950170-24-029889","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Enanta shareholders approve 975,000-share increase to 2019 Equity Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2019 Equity Incentive Plan, increasing share reserve by 975,000 shares.","Re-elected Class II directors Yujiro S. Hata, Kristine Peterson, and Terry C. Vance.","Advisory say-on-pay vote passed with 12,306,697 votes for (79.4% of votes cast).","Ratified PricewaterhouseCoopers LLP as independent auditor for FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240265,"accession_number":"0000950170-24-012186","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2024-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta Q1 revenue $18M, net loss $33.4M; RSV data expected Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $18.0M (down from $23.6M YoY) from AbbVie's MAVYRET royalties; net loss $33.4M ($1.58/share) vs $29.0M loss YoY.","Cash and marketable securities $337.2M; expected to fund operations through fiscal 2027.","Anticipates topline data from RSVPEDs Phase 2 study of zelicapavir and EDP-323 Phase 2a challenge study in Q3 2024.","Expanded into immunology with oral KIT inhibitor program for chronic spontaneous urticaria; development candidate selection targeted for 2024.","G&A expenses rose to $16.5M due to legal fees from patent infringement suit against Pfizer and higher stock compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":18003000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257768,"accession_number":"0001193125-23-303014","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2023-12-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Enanta SVP & General Counsel Gardiner to retire by March 31, 2024; consulting role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nathaniel S. Gardiner, age 70, plans to retire as SVP and General Counsel on or before March 31, 2024.","Company expects to enter a consulting agreement with Gardiner for up to one year post-retirement.","No successor has been named; search process not disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257767,"accession_number":"0000950170-23-065087","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta reports Q4 net loss $28.1M; initiates EDP-323 Phase 2a RSV study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $18.9M (down from $20.3M YoY); FY revenue $79.2M (down from $86.2M).","Net loss $28.1M ($1.33/diluted share) vs $26.3M ($1.27) in Q4 2022; FY loss $133.8M ($6.38) vs $121.8M ($5.91).","Cash and marketable securities $370M; expects to fund operations through fiscal 2027.","FY2024 guidance: R&D $100-120M (down from $163.5M actual), G&A $45-50M (down from $52M).","Initiated Phase 2a challenge study for RSV candidate EDP-323; data expected Q3 2024. Advancing EDP-938 Phase 2 trials."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":79204000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":275120,"accession_number":"0000950170-23-039051","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta Q3 loss $1.86/diluted share; revenue $18.9M; positive Phase 1 RSV data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $39.1M ($1.86/diluted) vs. $31.7M ($1.53) in prior-year Q3; revenue $18.9M down from $19.5M.","Cash and marketable securities $392.5M at June 30; sold 54.5% of future royalty to OMERS for $200M.","Positive Phase 1 data for RSV L-protein inhibitor EDP-323; Phase 2 human challenge study expected early Q4 2023.","Updated FY2023 guidance: R&D $165M-$175M; G&A $50M-$55M; royalty portion to OMERS from Q4 onward.","Phase 2 COVID EDP-235 showed 1.0 log viral load drop in nucleocapsid-negative patients treated within 3 days."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":60272000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292529,"accession_number":"0000950170-23-026739","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2023-06-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Enanta EDP-235 shows 0.8-1.0 log viral load decline in Phase 2 COVID-19 trial subset","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In nucleocapsid-negative patients, 400mg EDP-235 showed 0.8 log viral load decline vs placebo at Day 5.","In subset treated within 3 days of symptom onset, 1.0 log viral load decline seen at Day 5.","Results support further development of EDP-235 for COVID-19.","Updated corporate presentation with additional SPRINT analyses posted on website June 7, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292528,"accession_number":"0000950170-23-018788","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta Q2 net loss widens to $37.7M; reports positive Phase 2 COVID-19 data, $200M royalty sale","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $37.7M ($1.79 loss/diluted share) vs $33.6M loss ($1.63) YoY; revenue $17.8M from HCV royalties.","Positive Phase 2 SPRINT data for EDP-235 (COVID-19): met primary endpoint; 400mg showed symptom improvement vs placebo.","Sold 54.5% of future MAVYRET royalties to OMERS for $200M upfront; cash runway extended into calendar 2026.","Cash and marketable securities $225.1M at March 31, 2023; plus remaining 45.5% royalty stream after cap.","Phase 1 data for RSV L-protein inhibitor EDP-323 expected in June; dual hMPV/RSV candidate selection in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":41380000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292527,"accession_number":"0001193125-23-122434","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Enanta sells 54.5% of MAVYRET royalties to OMERS for $200M; non-dilutive funding","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 54.5% of future royalty payments on MAVYRET/MAVIRET worldwide sales to OMERS Life Sciences for $200M.","OMERS receives royalty payments from July 2023 through June 2032, capped at 1.42x purchase price ($284M).","Enanta retains 45.5% of royalties until cap is reached, then 100% reverts to Enanta.","Proceeds to fund clinical development of pipeline therapies for viral infections; transaction is non-dilutive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313198,"accession_number":"0000950170-23-007317","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Enanta reports <5% cash held at SVB; no material impact on runway","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Less than ~5% of Enanta's cash and marketable securities were in Silicon Valley Bank operating accounts.","Remaining investments held in custody accounts at an independent institution.","No material impact on projected cash runway or operations from SVB exposure.","Disclosure made on March 10, 2023 amid SVB liquidity crisis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313197,"accession_number":"0000950170-23-006453","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Enanta stockholders re-elect directors, approve equity plan amendment and say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected Bruce L.A. Carter and Jay R. Luly as Class I directors with 14.3M and 16.7M votes for.","Approved amendment to 2019 Equity Incentive Plan to increase authorized shares by 975,000.","Advisory say-on-pay vote approved with 16.2M votes for versus 1.4M against.","Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal year 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":313196,"accession_number":"0000950170-23-001981","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2023-02-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta reports Q1 net loss $29M; SPRINT Phase 2 COVID-19 study fully enrolled with data expected May 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $23.6M, down from $27.6M YoY, primarily from MAVYRET royalties.","Net loss $29.0M ($1.39 loss per share) vs $30.1M ($1.48 loss per share) YoY.","Cash $241.4M; expects runway into Q4 fiscal 2024.","Enrollment complete in Phase 2 SPRINT study of EDP-235 (COVID-19); topline data expected May 2023.","Expects Phase 1 data for EDP-323 (RSV) in Q2 2023; new PLpro and dual hMPV/RSV programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":23585000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331720,"accession_number":"0000950170-22-025532","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2022-11-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta reports Q4 net loss $26.3M, revenue $20.3M; initiates Phase 2 COVID-19 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 royalty revenue $20.3M (down 14% YoY); full year revenue $86.2M vs $97.1M.","Q4 net loss $26.3M ($1.27 loss per share) vs $24.6M loss ($1.22) prior year.","Cash $278.5M; expects runway into Q4 fiscal 2024.","Initiated Phase 2 SPRINT trial of oral 3CL protease inhibitor EDP-235 for mild/moderate COVID-19.","FY2023 guidance: R&D $210-230M, G&A $46-52M."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":86160000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349212,"accession_number":"0001193125-22-231310","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2022-08-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Enanta Pharmaceuticals enters ATM agreement with Jefferies for up to $100M common stock offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Open Market Sale Agreement with Jefferies LLC allows at-the-market sales of up to $100M in common stock.","Jefferies will receive a 3.0% commission on gross sales price per share sold under the agreement.","Shares sold on Nasdaq Global Select Market or other trading venues; company has no obligation to sell.","Offering terminates upon sale of all shares or termination of the agreement per its terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":349211,"accession_number":"0000950170-22-015505","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta posts Q3 loss of $31.7M; sues Pfizer for Paxlovid patent infringement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $31.7M ($1.53 diluted loss per share) vs $24.0M loss ($1.19) in prior year; revenue $19.5M from AbbVie royalties, down from $21.6M.","Cash, equivalents and marketable securities $292.7M; expects sufficient for two years.","Filed patent infringement suit against Pfizer over Paxlovid; seeks damages, not injunction; patent awarded June 2022.","EDP-235 Phase 1 data positive; Phase 2 study planned Q4 2022; RSV programs include new Phase 2 studies for EDP-938 and EDP-323.","Appointed Scott T. Rottinghaus as SVP and Chief Medical Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":65843000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366102,"accession_number":"0001193125-22-178106","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2022-06-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Enanta sues Pfizer for patent infringement over Paxlovid, seeks damages only","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed suit against Pfizer in U.S. District Court for Massachusetts over U.S. Patent No. 11,358,953 covering coronavirus protease inhibitors.","Patent was awarded earlier in June 2022 based on a July 2020 application; Enanta claims Pfizer's Paxlovid infringes.","Enanta states it will not seek an injunction or take action to block production, sale, or distribution of Paxlovid.","Enanta seeks 'fair compensation' for Pfizer's use of the coronavirus protease inhibitor claimed in the '953 patent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366101,"accession_number":"0001193125-22-153071","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2022-05-17T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Enanta signs 10-year lease for ~73k sq ft HQ expansion in Watertown, MA; amends existing leases","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New lease with ARE-MA Region No. 75 for ~73,000 sq ft at Arsenal on the Charles; 10-year term starting June 2024.","Aggregate minimum lease payments under new lease: ~$76.5M; base rent ~$0.6M/month with 3% annual escalations.","Tenant improvement allowance of ~$15.0M; one-time extension option for additional 5 years at market rate.","Second Amendment shortens 500 Arsenal St lease to ~June 2024; aggregate remaining payments ~$6.5M.","First Amendment at 400 Talcott Ave adds ~20,000 sq ft office space; lease extended to June 2034; aggregate payments ~$19.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":366100,"accession_number":"0000950170-22-008469","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta reports Q2 net loss of $33.6M; revenue down to $18.7M on lower HCV royalties","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $33.6M ($1.63/share) vs. loss of $22.0M ($1.09/share) last year.","Total revenue of $18.7M, down 7% YoY, all royalty from AbbVie's HCV regimen MAVYRET.","Cash and securities $322.5M; expects to fund operations for at least two years.","Expects topline data from RSVP Phase 2b study of EDP-938 in adults with RSV this quarter.","FDA Fast Track for EDP-235 (COVID-19); preliminary Phase 1 data expected this quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":46364000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385593,"accession_number":"0000950170-22-003221","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2022-03-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Enanta Pharmaceuticals amends equity plan, adds 1.05M shares for issuance","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to 2019 Equity Incentive Plan at March 3, 2022 annual meeting.","Increase of 1,050,000 shares of common stock reserved for issuance under the plan.","Plan as amended filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385592,"accession_number":"0000950170-22-003118","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2022-03-08T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Enanta stockholders approve all proposals at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Mark Foletta (16,269,503 votes for) and Lesley Russell (16,081,968 votes for) as Class III directors.","Approved amendment to 2019 Equity Incentive Plan, increasing reserved shares by 1,050,000.","Advisory say-on-pay proposal passed with 16,369,060 votes for, 933,286 against.","Ratified PricewaterhouseCoopers LLP as independent auditor for fiscal 2022 with 18,378,176 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":385591,"accession_number":"0000950170-22-000875","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2022-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta Q1 net loss $30.1M; plans to start EDP-235 Phase 1 this month","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $30.1M ($1.48 per diluted share) vs $8.3M loss in prior-year quarter.","Royalty revenue from MAVYRET/MAVIRET was $27.6M, down from $31.7M YoY.","R&D expenses rose to $48.5M from $36.7M due to manufacturing for virology programs.","Cash and marketable securities $347.7M; expects sufficient runway for at least two years.","EDP-235 (oral COVID-19 treatment) Phase 1 dosing begins Feb 2022; RSVP topline data expected Q2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":27648000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":403470,"accession_number":"0000950170-21-004845","cik":1177648,"company_name":"ENANTA PHARMACEUTICALS INC","ticker":"ENTA","form_type":"8-K","filed_at":"2021-11-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Enanta Pharma Q4 net loss $24.6M; FY net loss $79M; terminates HBV asset, plans COVID protease inhibitor","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $23.6M (flat YoY); net loss $24.6M ($1.22 loss per diluted share) vs $29.3M loss a year ago.","FY revenue $97.1M (down 21% from $122.5M); net loss $79M ($3.92 loss per diluted share) vs $36.2M loss.","Terminated EDP-721 (HBV RNA destabilizer) due to adverse safety signals; positive Phase 1b data for EDP-514 HBV core inhibitor.","Plans to advance EDP-235 oral protease inhibitor for COVID-19 into Phase 1 in early 2022.","Discontinued internal NASH FXR agonist development; will pursue out-licensing; FY2022 guidance: R&D $150-170M, G&A $35-41M."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":97074000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":387178625.46019715,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}